StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock. Several other research analysts also recently issued reports on NVTA. The Goldman Sachs Group downgraded shares of Invitae from a neutral rating […]
Invitae Co. (NYSE:NVTA – Get Rating) CEO Kenneth D. Knight sold 45,432 shares of the stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $1.20, for a total transaction of $54,518.40. Following the completion of the transaction, the chief executive officer now owns 1,671,610 shares of the […]
Stock analysts at StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA – Get Rating) in a research note issued on Thursday. The firm set a “sell” rating on the medical research company’s stock. A number of other research analysts also recently commented on the company. The Goldman Sachs Group downgraded Invitae from a “neutral” rating […]
Raymond James downgraded shares of Invitae (NYSE:NVTA – Get Rating) from a market perform rating to an underperform rating in a report issued on Monday morning, The Fly reports. A number of other equities analysts also recently commented on NVTA. Piper Sandler reduced their price objective on shares of Invitae from $2.25 to $1.75 and […]
Invitae (NYSE:NVTA – Get Rating) had its price target decreased by Piper Sandler from $1.75 to $1.50 in a research report released on Monday, The Fly reports. A number of other analysts have also weighed in on the stock. StockNews.com began coverage on shares of Invitae in a research note on Thursday, March 16th. They […]